renal cell carcinoma

Aveo Oncology’s kidney cancer drug gets FDA nod, 8 years after stinging rejection

In two pivotal studies years apart, Aveo Oncology’s drug tivozanib did not help kidney cancer patients live longer overall compared to the standard of care. The FDA approved still approved it, the latest development in a long saga that includes several regulatory stumbles.

By Frank Vinluan

BioPharma

AVEO Oncology puts off seeking FDA approval for kidney cancer drug until 1Q20

The agency told the company it still had lingering reservations about the results of a Phase III trial that had been designed to allay agency concerns. Shares of the company fell 38 percent on the news.

By Alaric DeArment

Health IT

Transforming Patient Care: The Role of AI-Powered Assistants

The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.

By IT Medical

Health IT

Reducing Clinical and Staff Burnout with AI Automation

As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.

By Dr. Michael Blackman, Chief Medical Officer at Greenway Health

Health IT

Reducing Clinical and Staff Burnout with AI Automation

As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.

By Dr. Michael Blackman, Chief Medical Officer at Greenway Health

Aveo Oncology’s kidney cancer drug gets FDA nod, 8 years after stinging rejection

AVEO Oncology puts off seeking FDA approval for kidney cancer drug until 1Q20

Market Trends to Watch for Health Systems and Their Specialty Pharmacies